Valuation: StemRIM

Market Cap 18.68B 118M 105M 98.21M 89.52M 169M 11.38B 170M 1.19B 461M 5.82B 445M 435M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 74.09M 65.83M 61.44M 56M 106M 7.12B 107M 743M 288M 3.64B 278M 272M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
1 day-3.53%
1 week-6.29%
Current month-3.53%
1 month-47.60%
3 months-47.10%
6 months-46.58%
Current year-37.64%
1 week 161
Extreme 161
185
1 month 161
Extreme 161
337
Current year 161
Extreme 161
368
1 year 161
Extreme 161
368
3 years 161
Extreme 161
752
5 years 161
Extreme 161
1,518
10 years 161
Extreme 161
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2022-09-30
Chief Executive Officer 58 2023-10-24
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 2007-01-31
Director/Board Member 58 2019-02-28
Director/Board Member 54 2019-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%-6.29%-43.45%-78.31% 65.18M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.56%-3.68%+20.11%+43.61% 369.73B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.95%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.82M -11.39M -10.63M -9.69M -18.28M -1.23B -18.45M -129M -49.85M -630M -48.13M -47.09M -1.93B -12.23M -10.87M -10.14M -9.24M -17.43M -1.18B -17.6M -123M -47.56M -601M -45.92M -44.92M
Net Debt -8.41B -53.32M -47.38M -44.22M -40.3M -76.01M -5.13B -76.72M -535M -207M -2.62B -200M -196M -6.99B -44.34M -39.4M -36.77M -33.52M -63.21M -4.26B -63.8M -445M -172M -2.18B -166M -163M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
26-10-02 JP¥164.00 -3.53% 252,800
26-10-01 JP¥170.00 0.00% 257,900
26-09-30 JP¥170.00 +2.41% 439,300
26-09-29 JP¥166.00 -3.49% 598,400
26-09-28 JP¥172.00 -1.71% 550,400
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock